Immune checkpoint inhibitor-associated inflammatory arthritis.
文献摘要
Immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) represents the most common rheumatic immune-related adverse event, characterized by a distinct clonal expansion of CD8 + T cells that often mirrors the immune pathways driving antitumour responses. Clinically, ICI-IA presents with diverse phenotypes, including polyarticular and oligoarticular patterns, and is notably persistent, often continuing as a chronic condition long after the cessation of immunotherapy. Unlike traditional autoimmune arthritis, ICI-IA is predominantly seronegative, making diagnosis reliant on clinical recognition and the exclusion of mimics such as metastatic cancer and other immune-related adverse events. Management strategies prioritize symptom optimization to maintain patient quality of life and facilitate the continuation of life-saving cancer therapy. Treatment includes glucocorticoids and increasing use of conventional and biologic DMARDs. This approach is aimed at minimizing glucocorticoid toxicity while preserving the efficacy of the checkpoint inhibitor therapy, highlighting the need for a balanced, multidisciplinary approach to care.